相关实验视频
Updated: May 5, 2026

04:34
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
Published on: June 15, 2011
18.0K
遗传变异与绝经后妇女的非致命静脉血栓症的关联
Nicholas L Smith1, Lucia A Hindorff, Susan R Heckbert
1Department of Epidemiology, University of Washington, Seattle, WA 98101, USA. nlsmith@u.washington.edu
JAMA
|February 8, 2007
概括
研究了血液凝固基因的遗传变异,以确定绝经后妇女的静脉血栓 (VT) 风险. 五种单核酸多态 (SNP) 与静脉瘤风险有关,其中三种是需要进一步研究的新发现.
科学领域:
- 遗传学 是一个遗传学.
- 血栓形成的研究研究
- 流行病学 流行病学
背景情况:
- 遗传变异在静脉血栓形成 (VT) 风险中的作用尚未完全理解.
- 之前的研究已经对凝血蛋白进行了表征,但没有全面研究对静脉瘤的遗传贡献.
研究的目的:
- 研究24个候选基因中常见的遗传变异与发生非致命静脉血栓塞 (VT) 的风险之间的关联.
- 专注于绝经后的女性,以了解对静脉瘤的遗传倾向.
主要方法:
- 进行了一项基于人口的病例控制研究.
- 包括30-89岁的绝经后妇女,第一次发生VT事件 (n=349) 和匹配的对照 (n=1680).
- 使用单核型和单核酸多态 (SNP) 分析了常见的遗传变异,通过错误发现率 (q值) 评估重要性.
主要成果:
- 组织因子通路抑制基因的全球变异显示出与静脉瘤风险相关的趋势.
- 在因子V,因子XI和蛋白C基因中发现了五种与静脉瘤风险相关的显著单核酸多态 (SNP) 关联.
- 在五个显著的SNP中,有三个代表了新的发现,而两个证实了之前报告的关联.
结论:
- 在多次测试调整后,五个SNP与静脉血栓形成风险有关.
- 三种新的SNP协会需要在独立种群中复制.
- 鉴定影响绝经后妇女静脉瘤风险的遗传因素对于有针对性的预防策略至关重要.
相关概念视频
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

